Patient Community Is FDA’s “Guiding Light” On Acceptable Drug Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER’s Janet Woodcock says the community has the agency’s ear when it advocates new developments; cites need for an “adult conversation” in assessing when drugs should be made available to patients.